In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination.
In this study tumor-specific CTL effector and memory responses were analyzed in normal mice, in tumor bearing mice and in animals treated by active specific immunotherapy (ASI) with an autologous virus modified tumor vaccine. In the well defined DBA/2 mouse lymphoma model ESb, the tumor specific CTL response requires interactions of four different cell types and recognition of MHC class I and class II restricted tumor antigens either on host antigen presenting cells (APCs) or on the tumor cells. The most effective in situ activation of syngeneic tumor specific CTL can be generated within no more than 9 days by primary immunization in the ear pinna and restimulation in the peritoneal cavity. Here we describe modulatory effects of either cytokines or of virus infection of tumor stimulator cells during restimulation in the peritoneal cavity on the CTL memory response. The in situ peritoneal effector cell (PEC) response was augmented when Newcastle Disease Virus (NDV) was used to infect tumor cells which expressed the correct tumor associated antigen of the memory response but not when a third party tumor cell was infected and admixed. A response could also be augmented by co-administration of interferons-alpha, -beta or IL-2 and by pre-treatment with low dose cyclophosphamide. Therapeutic vaccination effects could be achieved in mice inoculated s.c. with this aggressive and metastatic tumor variant if the vaccine was given very early, i.e. 1-2 days after priming and when the vaccine was applied post-operatively, i.e. in situations of low tumor burden. A long-term CTL memory response could be demonstrated even two months after post-operative active specific immunotherapy with ESb-NDV vaccine.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Affiliations: German Cancer Research Center, Division of Cellular Immunology, D-69120 Heidelberg, Germany.
Publication date: January 1, 1999
More about this publication?
- The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites